William Martin Hilton, MD Urology Medicare: Not Enrolled in Medicare Practice Location: Landstuhl Regional Medical Center, Cmr 402, Apo, AE 09180 Phone: 496-371-9464 |
Dr. Richard B. Knight, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: Psc 41 Box 375, Apo, AE 09464 Phone: 314-226-8186 |
Ashley Marie Henry, MD Urology Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center Unit 33100, Urology Clinic, Apo, AE 09180 Phone: 314-590-5859 |
Mrs. Sarah Bennett Starosta, M.D. Urology Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center, Cmr 402, Unit 33100, Apo, AE 09180 Phone: 314-590-7028 |
Suzanne Gudeman, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: Naval Hospital Rota Spain, Psc 819, Fpo, AE 09645 Phone: 314-727-3403 |
Bryan S. Buchanan, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: Psc 819 Box 18-100, Fpo, AE 09645 Phone: 011-349-56823415 |
News Archive
The Johnson & Johnson Medical Devices Companies today announced that DePuy Synthes has launched the CONDUIT Interbody Platform with EIT Cellular Titanium Technology, further expanding its comprehensive offering to treat degenerative spine disease.
A California agency, the Air Resources Board, which first linked secondhand smoke to heart disease, now says secondhand smoke causes breast cancer too.
Patients with colon cancer who used multivitamins during and after being treated with post-surgical chemotherapy did not reduce the risk of the cancer returning or their dying from it, according to researchers at Dana-Farber Cancer Institute.
Discovered more than two decades ago, the hormone leptin has been widely hailed as the key regulator of leanness. Yet, the pivotal experiments that probe the function of this protein and unravel the precise mechanism of its action as a guardian against obesity are largely missing.
Imagine Media, Ltd., a Delaware corporation today announced that it has signed a non-binding Letter of Intent to acquire DMI Life Sciences, Inc., a Denver, Colorado-based biotechnology company. ("DMI"). Under the terms of the LOI, if the acquisition is completed, the shareholders of DMI will acquire approximately 90.52% of the total issued and outstanding shares of the Company, and the transaction will constitute a change in control.
› Verified 4 days ago